La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Alpha Tau Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Alpha Tau Medical..

Alpha Tau Medical (NASDAQ:DRTS) Azioni, Catena delle Opzioni

Alpha Tau Medical

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.

Alpha Tau Medical Ltd

Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services sector, raising doubts about near-term rate cuts and <a href="https://www.benzinga.com/markets">weighing on risk appetite.</a>
The ISM Services PMI for April pointed to only marginal growth, the slowest since late 2023, while the index for prices paid surged to its highest reading in more than two years, reflecting a sharp rise in input costs amid renewed trade disruptions tied to tariffs announced last month by President Donald Trump.
The S&amp;P 500 slipped 0.2% to 5,670, while the Nasdaq 100 matched the decline to 20,050. The Dow Jones Industrial Average, however, managed a modest 0.2% gain. If the S&amp;P 500 closes higher, it would mark its tenth consecutive session of gains, the longest winning streak since September 1995.
Rising bond yields pressured equities, with the 10-year Treasury yield climbing 4 basis points to 4.35%, and the 30-year yield up at 4.83%.
Speaking at the Milken Institute, Treasury Secretary Scott Bessent said the U.S. was nearing agreements on new trade deals, potentially as soon as this week. He indicated that 17 trading partners, excluding China, had presented strong proposals, and suggested that meaningful progress with China could also emerge in the coming weeks.
Meanwhile, oil prices dropped 2% to $57 a barrel following OPEC+'s signal of a 411,000 bpd production hike starting in June, with further increases possible over the summer.
Gold rallied 2%, on track for its strongest session in two weeks, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady near $94,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,418.85</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,677.19</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,016.46</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,057.89</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:42 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% down to $565.72.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.3% to $414.11.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $487.66.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% lower to $200.11.</li>
<li>The&nbsp;Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) outperformed, up 0.6%; the&nbsp;Energt Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) down 4.26%</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) up 2.07%</li>
<li>Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) down 7.63%</li>
<li>Zimmer Biomet Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) down 9.28%</li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) down 1.29%</li>
<li>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) down 8.17%</li>
<li>Henry Schein Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) up 0.86%</li>
</ul>
Stocks scheduled to report earnings after the close include Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), The Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>), Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>), Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>), The Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>), Celanese Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>), Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) and Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45198741/goldman-sachs-issues-bearish-40-oil-forecast-as-opec-pumps-more-energy-stocks-sink">Goldman Sachs Issues Bearish $40 Oil Forecast As OPEC+ Pumps More: Energy Stocks Sink</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Analyst Ratings

Tech

ETFs

$BTC

CTRA

SPDR Dow Jones Industrial Average ETF Trust

FANG

HSIC

LSCC

PLTR

VRTX

Select Sector SPDR-Consumer Discretionary

Stocks Pause Gains As Treasury Yields Rise: What's Driving Markets Monday?

Lake Street analyst Ben Haynor maintains Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) with a Buy and lowers the price target from $5 to $4.

News

Price Target

BFLY

Lake Street Maintains Buy on Butterfly Network, Lowers Price Target to $4

Piper Sandler analyst Kashy Harrison maintains MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight and raises the price target from $134 to $175.

Piper Sandler Maintains Overweight on MasTec, Raises Price Target to $175

Lake Street analyst Jaeson Schmidt maintains inTest (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INTT#AMEX">INTT</a>) with a Buy and lowers the price target from $10 to $8.

INTT

Lake Street Maintains Buy on inTest, Lowers Price Target to $8

Hypersale Data, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock stock is trading higher Monday after the company issued preliminary sales guidance for the first-quarter and <a href="https://www.benzinga.com//node/45189872">full fiscal-year 2025.</a>
What To Know: The company expects to report $25 million in first-quarter revenue. The company also guided for full-year revenue of $115 million to $125 million.
Hyperscale noted that it reported a significant one-time gain of approximately $9.7 million in the first-quarter. The company attributed this to deconsolidation of Avalanche International Corp. 
&#8220;2025 is off to a strong start with growth across several of our core businesses,&#8221; said William B. Horne, CEO of Hyperscale. &#8220;Our transition of the Michigan facility to an AI data center and partial divestment of non-core assets are key milestones as we position Hyperscale Data for long-term success.&#8221;
Hyperscale shares are trading more than 400% higher. The company's micro-cap status, with a market capitalization of $2.09 million, may be contributing to the stock's volatility.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45199299/ripple-commits-25m-to-us-teachers-and-classrooms-via-rlusd-stablecoin">Ripple Commits $25M To US Teachers And Classrooms Via RLUSD Stablecoin</a>
GPUS Price Action: At the time of writing, Hyperscale stock is trading 468% higher at $7.78, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

Movers

GPUS

Hyperscale Data Stock Soars On Preliminary Q1 And FY25 Guidance

Piper Sandler analyst Kashy Harrison maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Neutral and lowers the price target from $124 to $121.

ITRI

Piper Sandler Maintains Neutral on Itron, Lowers Price Target to $121

Loop Capital analyst Anthony Chukumba maintains Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) with a Hold and raises the price target from $85 to $90.

FIVE

Loop Capital Maintains Hold on Five Below, Raises Price Target to $90

Occidental Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) shares fell 3.37% to $39.24 on Monday, tracking a broader decline in oil-related stocks after OPEC+ announced a <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze">significant output</a> increase. 
What To Know: OPEC+ plans to boost production by 411,000 barrels per day in June, adding to similar increases in April and May. The combined rise of 960,000 bpd reverses nearly half of the voluntary supply cuts enacted since 2022.
The move, largely driven by Saudi Arabia, aims to <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze">enforce production discipline</a> within the group and regain market share from overproducing members like Iraq and Kazakhstan. 
However, the market reacted negatively, with WTI crude futures dropping nearly 2% to just under $57 per barrel—well below the $65 threshold many U.S. oil producers, including Occidental, need to sustain profitability.
What Else: Occidental is set to report first-quarter <a href="https://www.benzinga.com/quote/OXY/earnings">earnings</a> after the market closes Wednesday, with analysts expecting EPS of 74 cents on revenue of $6.97 billion. 
The sharp drop in crude prices may raise investor concerns about margins and future cash flow, putting added pressure on the stock ahead of the results.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45192936/wall-street-veteran-investor-lowers-recession-risk-as-us-china-trade-war-cools">Wall Street Veteran Investor Lowers Recession Risk As US-China Trade War Cools</a>
<h2 class="wp-block-heading">How To Buy OXY Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Occidental Petroleum&#8217;s case, it is in the Energy sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, OXY has a 52-week high of $65.78 and a 52-week low of $34.78.

Occidental Petroleum (OXY) Stock Drops As Oil Prices Slide Ahead Of Earnings Report

Loop Capital analyst Alton Stump maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Buy and lowers the price target from $26 to $21.

Loop Capital Maintains Buy on Wendy's, Lowers Price Target to $21

Piper Sandler analyst Kashy Harrison maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Overweight and lowers the price target from $31 to $26.

Piper Sandler Maintains Overweight on Bloom Energy, Lowers Price Target to $26

Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Overweight and lowers the price target from $16 to $12.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $12

Piper Sandler analyst Korinne Wolfmeyer maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Neutral and raises the price target from $160 to $164.

Piper Sandler Maintains Neutral on Procter & Gamble, Raises Price Target to $164

Barclays analyst Michael Leithead maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Overweight and lowers the price target from $135 to $100.

Barclays Maintains Overweight on Westlake, Lowers Price Target to $100

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Equal-Weight and raises the price target from $35 to $37.

Barclays Maintains Equal-Weight on Valaris, Raises Price Target to $37

Editor&#8217;s note: This article has been updated to remove a reference to Ken Griffin&#8217;s political affiliations.
Ken Griffin, founder of hedge‑fund giant Citadel LLC, told Stanford business students that career growth hinges on surrounding oneself with sharper minds, not basking as "the smartest person in the room."
What Happened: In a "View From the Top" interview posted this week, Griffin recalled college days cold‑calling Bear Stearns traders for tips on convertible bonds and said that habit still guides him.
"If you're the smartest person in the room, you have so screwed up your Stanford MBA," he warned, adding, "You don't want to be the smartest person in the room." Griffin praised Citadel's brain trust, noting a Europe‑based employee who cracked "a tough math problem" overnight after others were stumped.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="View From The Top with Ken Griffin, Founder and CEO of Citadel" width="500" height="281" src="https://www.youtube.com/embed/GuF14oKon8A?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Griffin, 56, built Citadel from a Harvard dorm‑room trading venture in 1990 into a multistrategy powerhouse managing about $65 billion in investment capital and employing more than 3,100 people. Forbes <a href="https://www.forbes.com/profile/ken-griffin/">pegs his net worth</a> at $42.5 billion, making him one of America's richest financiers.
See also:<a href="https://www.benzinga.com/news/management/25/05/45166556/jeff-bezos-says-the-hardest-thing-was-landing-amazons-first-million-says-he-warned-potential-backers-of-a-70-chance-theyd-lose-their-money"> Jeff Bezos Says The &#8216;Hardest Thing&#8217; Was Landing Amazon&#8217;s First Million, Says He Warned Potential Backers Of A &#8216;70% Chance&#8217; They&#8217;d Lose Their Money</a>
He told students their first job choice should be "a learning environment," stressing that lessons flow from colleagues, clients, even rivals. American business culture, he said, is "generationally kind and generous," and executives have a duty to pass knowledge forward. "It's part of the magic of America that we share insights across generations," Griffin said.
Citadel's own culture of constant learning has paid off: its flagship Wellington fund gained 1.3 percent in April despite volatile markets, reveals a WSJ <a href="https://www.wsj.com/finance/investing/citadel-sidesteps-aprils-market-swoons-to-post-gains-across-its-funds-6cf7969e">report</a>, lifting year‑to‑date returns back into positive territory. Griffin urged the future MBAs to replicate that edge by seeking rooms where they can keep asking, "Explain this — what do you think about that?"
Why It Matters: Griffin recently <a href="https://www.benzinga.com/markets/equities/25/04/44972192/gop-megadonor-ken-griffin-urges-investors-to-tread-water-and-not-drown-amid-nonsensical-trade-policies-we-put-that-brand-at-risk">voiced his apprehensions</a> about the current market conditions, where he indicated that the market is shrinking too rapidly to generate substantial returns, stating, "There are no great opportunities." Griffin is among several affluent individuals who have <a href="https://www.benzinga.com/markets/25/04/44660599/stanley-druckenmiller-on-x-i-do-not-support-tariffs-exceeding-10-as-trump-digs-heels-on-trade-policy">expressed doubts</a> about the reasoning and execution of the recent tariffs.
Citadel largely avoided market turmoil, with its flagship fund down just 0.9% in Q1, compared to the S&amp;P 500&#8217;s decline of over 4%. Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) gained 1.25% over the past month while SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.31% during the same period.
Read next: <a href="https://www.benzinga.com/25/05/45165487/elon-musks-brother-backs-tesla-ceo-amid-report-of-board-exploring-ceo-replacement-its-getting-boring">Elon Musk&#8217;s Brother Backs Tesla CEO Amid Report Of Board Exploring CEO Replacement: &#8216;It&#8217;s Getting Boring&#8217;</a>
Image via Shutterstock

Management

Citadel Kingpin Ken Griffin Warns Being 'Smartest In The Room' Means You've 'Screwed Up' Your MBA (CORRECTED)

Piper Sandler analyst Peter Keith maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Neutral and lowers the price target from $12 to $10.

ARHS

Piper Sandler Maintains Neutral on Arhaus, Lowers Price Target to $10

Barclays analyst Andrew Lazar maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Equal-Weight and raises the price target from $160 to $165.

Barclays Maintains Equal-Weight on Hershey, Raises Price Target to $165

Piper Sandler analyst Peter Keith maintains YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Overweight and lowers the price target from $52 to $38.

YETI

Piper Sandler Maintains Overweight on YETI Holdings, Lowers Price Target to $38

Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) (&quot;Above Food&quot; and the &quot;Company&quot;) today releases the Palm Global Technologies (&quot;Palm Global&quot;) announced launch of Palm Promax Investments (&quot;Palm Promax&quot;) <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4419921-1&amp;h=3620235721&amp;u=http%3A%2F%2Fwww.palmpromax.com%2F&amp;a=www.palmpromax.com">www.palmpromax.com</a>, a strategic joint venture between Palm Global and Abu Dhabi conglomerate, Promax United LLC (&quot;Promax UAE&quot;).&nbsp;
Palm Promax seeks to redefine the global financial landscape through the development of next generation investment products and platforms powered by Palm Global&#39;s advanced blockchain, Artificial Intelligence and Web-3 technologies. Its vision is built upon two primary objectives, the creation of the world&#39;s leading digital fixed-income platform and the establishment of the world&#39;s most globally recognized stablecoin digital asset. Both initiatives are anchored by the tokenization of over $1.5 trillion in AA and AAA-rated Real-World Assets and backed by sovereign partnerships in more than fifteen nations.
Underpinned by Promax UAE&#39;s unparalleled access to Real-World Assets and powered by Palm Global&#39;s highly scalable AI driven DeFi ecosystem, Palm Promax has launched with an initial injection of approximately $350 billion in U.S. gold-based assets onto the joint venture&#39;s balance sheet. These assets serve to securitize and anchor its fixed income platform and stablecoin. Through Palm Global&#39;s 30% ownership stake in Palm Promax and its underlying assets, Palm Global will recognize its share of the substantial high-margin revenues, earnings and cash flows generated by the joint venture&#39;s operations.
Promax UAE owns a number of semi-government subsidiary companies, which provide strategic financial access through their direct engagement with central banks globally. This is expected to facilitate the widespread adoption of Palm Promax&#39;s gold-backed stablecoin. With more than fifteen sovereign partnerships already committed to the project, the stablecoin is also designed to address challenges faced by nations whose domestic currencies are not widely accepted for international trade, providing a viable solution to facilitate global commerce.
Chairman of Palm Global, Peter Knez, commented:&nbsp;&quot;As the global financial landscape undergoes a seismic shift and the digital world enters a new paradigm, with the United States and other nations introducing regulatory frameworks and strengthening oversight of cryptocurrencies and tokenization, investor confidence in digital assets continues to grow.
Meanwhile, trillions of dollars in private assets, gold, real estate, infrastructure remain trapped in illiquidity, inaccessible to investors and undervalued by markets. With Palm Promax&#39;s unique combination of institutional expertise, highly scalable artificial intelligence and cutting-edge blockchain technologies, we are poised to unlock this vast potential, not merely as participants in the financial transformation but to lead as its architects.
I am thrilled that, through our partnership with Promax UAE, Palm Promax is positioned to become the world&#39;s leading provider of tokenized asset-backed fixed-income funds, stablecoins, and investment platforms. With assets collateralized by gold, AA- and AAA-rated instruments, distinguished by strong histories of positive cash flow, our products and platforms will gain global recognition, enabling us to compete directly with government treasuries and bonds while offering competitive yields. This, I believe, will be truly transformative for the fixed-income investment market and the broader financial sector.
Our distinct advantages have already attracted the support of numerous sovereign wealth funds and central banks, including our esteemed partner, the Central Bank of the UAE. As part of our strategic vision, we are set to launch what we anticipate will be the world&#39;s largest asset-backed stablecoin. This initiative is designed to empower developing economies, including the fifteen African nations we are already working with, by providing a currency that is freely tradable and globally accepted, significantly strengthening their economic standing.
Beyond conventional assets, Palm Promax is pioneering the valuation of nature itself. Carbon credits, biodiversity reserves, AgTech and ecosystem services will soon be integrated into our platform, because true sustainability must align profitability with planetary stewardship. Tokenization is not merely a financial innovation; it is a catalyst for redefining how the world invests in its future.&quot;
His Excellency Louai Mohamed Ali, Group President of Promax United LLC, commented:&nbsp;&quot;We are thrilled to partner with Palm Global, bringing together all the essential elements to establish a universally recognized, world-leading fixed-income platform, a ubiquitous digital currency, and an unrivaled position as the global leader in the tokenization of real-world assets.
It has been many years since Peter was at the forefront of the ETF industry at Barclays and BlackRock, helping to shape what is now a $14 trillion market. Today, with Palm Promax, we stand at the precipice of an even greater financial evolution. We are poised to introduce a portfolio of products that will not only surpass this achievement but redefine the investment landscape, with our tokenized, real-world asset-backed funds, products, and stablecoin at its core.

Penny Stocks

Contracts

ABVE

Above Food Ingredients Announces Palm Global Technologies Launch Of Palm Promax Investments, A Strategic Joint Venture Between Palm Global And Promax United

Barclays analyst Benjamin Budish maintains T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Underweight and raises the price target from $85 to $90.

TROW

Barclays Maintains Underweight on T. Rowe Price Group, Raises Price Target to $90

Press Releases

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Health Care

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

Comments

Alpha Tau Medical

Alpha Tau Medical (DRTS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO